X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Paxtrava (travoprost intracameral implant) is a prostaglandin analog. It is being evaluated for the treatment of patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: Paxtrava
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Details:
iDose® TR (travoprost intracameral implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
iDose® TR (Travoprost Intracameral Implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Celanese
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
iDose TR (travoprost intracameral implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to daily eye drop treatment.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
Glaukos will supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR (travoprost), a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glaukos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2023
Details:
iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to daily eye drop treatment.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to daily eye drop treatment.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
93% of Slow-Release iDose TR (travoprost) Subjects Remained Well-Controlled on the Same or Fewer IOP-Lowering Topical Medications at 12 Months After a Single Administration of iDose TR, Including 81% Completely Free of IOP-Lowering Medications.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The iDose TR Phase 3 clinical program consists of two clinical trials designed to compare the safety and efficacy of a single administration of one of two iDose TR models with different travoprost release rates to topical timolol ophthalmic solution, 0.5% BID.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
In the Phase 1 clinical trial, all cohorts experienced a mean reduction in IOP from baseline of 7-11 mm Hg of OTX-TIC with onset of action as early as two days after insertion.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: OTX-TIC
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
